Merakris Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative biologic drug therapies for chronic wounds, announced that it has successfully completed a Type C ...

An announcement from Q32 Bio ( ($QTTB) ) is now available. On November 28, 2025, Q32 Bio Inc. entered into an Asset Purchase Agreement with Akebia ...

Shares of Q32 jumped 78% in premarket trading, to $3.90, while Akebia's stock was roughly flat. Akebia said the product candidate, AKB-097, is believed to have applicability across a wide range of ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement | Akebia Therapeutics has struck a deal for Q32 ...

The Center supports clients across the development and manufacturing of biologics, RNA therapeutics, vaccines, and cell and gene therapies.

Next-Generation Biologics and Biosimilars Market to Hit 251.13 billion Dollars by 2033 - Strategic Revenue Insights (SRI) ...

LENZ Therapeutics' newly approved presbyopia drop sits in a category with only one real commercial predecessor—AbbVie’s Vuity ...

Q32 Bio stock soared after the biotech firm divested its ADX-097 to Akebia Therapeutics for $12 million. Here’s how you ...

Bristol Myers Squibb said it will enroll more patients in a key Phase 3 trial studying its drug Cobenfy in psychosis associated with Alzheimer’s disease, after the company found “irregularities due to ...

A research team led by professor Olivia Merkel, Chair of Drug Delivery at LMU and co-spokesperson of the Cluster for Nucleic ...

In case you haven't guessed it already, the big thing to wait on before buying any shares of Summit Therapeutics is the FDA's ...

The Aura Plus system delivers fast, decisive, low volume particle characterization to support critical decision making in ...